PMID- 33318581
OWN - NLM
STAT- MEDLINE
DCOM- 20211214
LR  - 20230210
IS  - 1530-0285 (Electronic)
IS  - 0893-3952 (Linking)
VI  - 34
IP  - 5
DP  - 2021 May
TI  - Recurrent FOS rearrangement in proliferative fasciitis/proliferative myositis.
PG  - 942-950
LID - 10.1038/s41379-020-00725-2 [doi]
AB  - Proliferative fasciitis (PF) and proliferative myositis (PM) are rare benign soft 
      tissue lesions, usually affecting the extremities of middle-aged or older adults. 
      Presenting as poorly circumscribed masses, they histologically show bland spindle 
      cell proliferation in a myxoid to fibrous background and a hallmark component of 
      large epithelioid "ganglion-like" cells in various numbers, which may lead to 
      their misdiagnosis as sarcoma. PF/PM has been long considered as reactive, akin 
      to nodular fasciitis; however, its pathogenesis has remained unknown. In this 
      study, we analyzed the FOS status in 6 PF/PMs (5 PFs and 1 PM). Five PF/PMs 
      occurred in adults, all showing diffuse strong expression of c-FOS primarily in 
      the epithelioid cells, whereas spindle cell components were largely negative. 
      Using fluorescence in situ hybridization (FISH), all 5 c-FOS-immunopositive 
      tumors showed evidence of FOS gene rearrangement in the epithelioid cells. RNA 
      sequencing in 1 case detected a FOS-VIM fusion transcript, which was subsequently 
      validated by reverse transcriptase-polymerase chain reaction, Sanger sequencing, 
      and VIM FISH. The one pediatric PF case lacked c-FOS expression and FOS 
      rearrangement. c-FOS immunohistochemistry was negative in 45 cases of selected 
      mesenchymal tumor types with epithelioid components that may histologically mimic 
      PF/PM, including pleomorphic sarcoma with epithelioid features and epithelioid 
      sarcoma. Recurrent FOS rearrangement and c-FOS overexpression in PF/PM suggested 
      these lesions to be neoplastic. FOS abnormality was largely restricted to the 
      epithelioid cell population, clarifying the histological composition of at least 
      2 different cell types. c-FOS immunohistochemistry may serve as a useful adjunct 
      to accurately distinguish PF/PM from mimics.
FAU - Makise, Naohiro
AU  - Makise N
AUID- ORCID: 0000-0002-6991-747X
AD  - Department of Pathology, Graduate School of Medicine, The University of Tokyo, 
      Tokyo, Japan.
FAU - Mori, Taisuke
AU  - Mori T
AUID- ORCID: 0000-0003-1838-7883
AD  - Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, 
      Japan.
AD  - Division of Molecular Pathology, National Cancer Center Research Institute, 
      Tokyo, Japan.
FAU - Motoi, Toru
AU  - Motoi T
AD  - Department of Pathology, Tokyo Metropolitan Cancer and Infectious Diseases Center 
      Komagome Hospital, Tokyo, Japan.
FAU - Shibahara, Junji
AU  - Shibahara J
AD  - Department of Pathology, Kyorin University School of Medicine, Tokyo, Japan.
FAU - Ushiku, Tetsuo
AU  - Ushiku T
AUID- ORCID: 0000-0002-1763-8380
AD  - Department of Pathology, Graduate School of Medicine, The University of Tokyo, 
      Tokyo, Japan.
FAU - Yoshida, Akihiko
AU  - Yoshida A
AD  - Department of Diagnostic Pathology, National Cancer Center Hospital, Tokyo, 
      Japan. akyoshid@ncc.go.jp.
AD  - Rare Cancer Center, National Cancer Center Hospital, Tokyo, Japan. 
      akyoshid@ncc.go.jp.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20201214
PL  - United States
TA  - Mod Pathol
JT  - Modern pathology : an official journal of the United States and Canadian Academy 
      of Pathology, Inc
JID - 8806605
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Proto-Oncogene Proteins c-fos)
SB  - IM
MH  - Biomarkers, Tumor
MH  - Fasciitis/*genetics/pathology
MH  - Female
MH  - *Gene Rearrangement
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Myositis/*genetics/pathology
MH  - Proto-Oncogene Proteins c-fos/*genetics
EDAT- 2020/12/16 06:00
MHDA- 2021/12/15 06:00
CRDT- 2020/12/15 06:00
PHST- 2020/09/04 00:00 [received]
PHST- 2020/11/05 00:00 [accepted]
PHST- 2020/10/09 00:00 [revised]
PHST- 2020/12/16 06:00 [pubmed]
PHST- 2021/12/15 06:00 [medline]
PHST- 2020/12/15 06:00 [entrez]
AID - S0893-3952(22)00623-8 [pii]
AID - 10.1038/s41379-020-00725-2 [doi]
PST - ppublish
SO  - Mod Pathol. 2021 May;34(5):942-950. doi: 10.1038/s41379-020-00725-2. Epub 2020 
      Dec 14.